CL2023000985A1 - Conjugados covalentes del dominio de unión al receptor del virus sars-cov-2; proteína portadora; composiciones vacunales - Google Patents

Conjugados covalentes del dominio de unión al receptor del virus sars-cov-2; proteína portadora; composiciones vacunales

Info

Publication number
CL2023000985A1
CL2023000985A1 CL2023000985A CL2023000985A CL2023000985A1 CL 2023000985 A1 CL2023000985 A1 CL 2023000985A1 CL 2023000985 A CL2023000985 A CL 2023000985A CL 2023000985 A CL2023000985 A CL 2023000985A CL 2023000985 A1 CL2023000985 A1 CL 2023000985A1
Authority
CL
Chile
Prior art keywords
cov
sars
virus
vaccine compositions
binding domain
Prior art date
Application number
CL2023000985A
Other languages
English (en)
Inventor
Valdés Balbín Yury
Guillermo Verez Bencomo Vicente
García Rivera Dagmar
Fernández Castillo Sonsire
Marta Rodríguez Noda Laura
Jesús Ramírez González Ubel
Sánchez Ramírez Belinda
Ojito Magaz Eduardo
Boggiano Ayo Tammy
Oliva Hernández Reynaldo
Santana Mederos Darielys
García Rivera Daniel
García Ricardo Manuel
Original Assignee
Inst Finlay De Vacunas
Ct Inmunologia Molecular
Univ La Habana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Finlay De Vacunas, Ct Inmunologia Molecular, Univ La Habana filed Critical Inst Finlay De Vacunas
Publication of CL2023000985A1 publication Critical patent/CL2023000985A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con la biotecnología, específicamente con el campo de la salud humana. Describe conjugados covalentes del dominio de unión al receptor del virus SARS-CoV-2 con una proteína portadora, el método para obtener esos conjugados y las composiciones vacunales que los contienen. Las composiciones vacunales que se describen en la presente invención son útiles en la prevención de la infección por el virus SARS-CoV-2 ya que inducen una potente respuesta de anticuerpos neutralizantes.
CL2023000985A 2020-10-05 2023-04-05 Conjugados covalentes del dominio de unión al receptor del virus sars-cov-2; proteína portadora; composiciones vacunales CL2023000985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000069A CU24689B1 (es) 2020-10-05 2020-10-05 CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y PROCEDIMIENTO DE OBTENCIÓN

Publications (1)

Publication Number Publication Date
CL2023000985A1 true CL2023000985A1 (es) 2023-12-01

Family

ID=78822472

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000985A CL2023000985A1 (es) 2020-10-05 2023-04-05 Conjugados covalentes del dominio de unión al receptor del virus sars-cov-2; proteína portadora; composiciones vacunales

Country Status (11)

Country Link
US (1) US20230381295A1 (es)
EP (1) EP4226947A1 (es)
JP (1) JP2023547045A (es)
KR (1) KR20230129223A (es)
CN (1) CN117177774A (es)
AU (1) AU2021355767A1 (es)
BR (1) BR112023006340A2 (es)
CA (1) CA3198217A1 (es)
CL (1) CL2023000985A1 (es)
CU (1) CU24689B1 (es)
WO (1) WO2022073528A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111217917B (zh) * 2020-02-26 2020-10-23 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
CN111606981B (zh) * 2020-05-27 2022-02-08 中国医学科学院基础医学研究所 Sars-cov冠状病毒s1蛋白多肽及其应用

Also Published As

Publication number Publication date
AU2021355767A1 (en) 2023-06-01
JP2023547045A (ja) 2023-11-09
CA3198217A1 (en) 2022-04-14
KR20230129223A (ko) 2023-09-07
EP4226947A1 (en) 2023-08-16
CU24689B1 (es) 2023-12-07
US20230381295A1 (en) 2023-11-30
WO2022073528A1 (es) 2022-04-14
BR112023006340A2 (pt) 2023-05-09
CN117177774A (zh) 2023-12-05
CU20200069A7 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
CY1124982T1 (el) Εμβολιο mycoplasma hyopneumoniae
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
BR112018014986A2 (pt) composição farmacêutica compreendendo construtos de anticorpo biespecífico
BR112016027912A2 (pt) molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
AR077756A1 (es) Anticuerpos especificos para bacterias gram-positivas
CY1121673T1 (el) Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
PE20190576A1 (es) Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas
PE20190737A1 (es) Anticuerpos anti-cd27
AR117465A1 (es) Anticuerpo humanizado anti-pd-1 humana
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos
UY37457A (es) Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y
CO2020014663A2 (es) Anticuerpo de repetición de dipéptidos (dpr) anti (poli-ga) derivado de humanos
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
EA202092202A1 (ru) Конструкции антител к ror
AR059647A1 (es) Antigenos vacunales quimericos contra el virus de la influenza aviar
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
UY38016A (es) Oligonucleótidos inmunoestimulantes
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma